Search

Your search keyword '"de Knegt, Gerjo J."' showing total 23 results
Start Over Author "de Knegt, Gerjo J."
23 results on '"de Knegt, Gerjo J."'

9. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR T

Author

de Steenwinkel, Jurriaan E.M., ten Kate, Marian T., de Knegt, Gerjo J., Kremer, Kristin, Aarnoutse, Rob E., Boeree, Martin J., Verbrugh, Henri A., van Soolingen, Dick, and Bakker-Woudenberg, Irma A.J.M.

Subjects
Antitubercular agents, Tuberculosis -- Drug therapy, Drugs, Public health, Health
Abstract

The emergence of Mycobacterium tuberculosis resistance to antituberculosis (anti-TB) drugs is a major public health challenge that is threatening World Health Organization targets set for the elimination of TB (1). [...]

Published
2012
Full Text
View/download PDF

15. Improving treatment outcome assessment in a mouse tuberculosis model

Author

Mourik, Bas C., Svensson, Robin J., de Knegt, Gerjo J., Bax, Hannelore I., Verbon, Annelies, Simonsson, Ulrika S H, de Steenwinkel, Jurriaan E. M., Mourik, Bas C., Svensson, Robin J., de Knegt, Gerjo J., Bax, Hannelore I., Verbon, Annelies, Simonsson, Ulrika S H, and de Steenwinkel, Jurriaan E. M.

Abstract

Preclinical treatment outcome evaluation of tuberculosis (TB) occurs primarily in mice. Current designs compare relapse rates of different regimens at selected time points, but lack information about the correlation between treatment length and treatment outcome, which is required to efficiently estimate a regimens' treatment-shortening potential. Therefore we developed a new approach. BALB/c mice were infected with a Mycobacterium tuberculosis Beijing genotype strain and were treated with rifapentine-pyrazinamide-isoniazid-ethambutol (R(p)ZHE), rifampicin-pyrazinamide-moxifloxacin-ethambutol (RZME) or rifampicin-pyrazinamide-moxifloxacin-isoniazid (RZMH). Treatment outcome was assessed in n = 3 mice after 9 different treatment lengths between 2-6 months. Next, we created a mathematical model that best fitted the observational data and used this for inter-regimen comparison. The observed data were best described by a sigmoidal E-max model in favor over linear or conventional E-max models. Estimating regimen-specific parameters showed significantly higher curative potentials for RZME and R(p)ZHE compared to RZMH. In conclusion, we provide a new design for treatment outcome evaluation in a mouse TB model, which (i) provides accurate tools for assessment of the relationship between treatment length and predicted cure, (ii) allows for efficient comparison between regimens and (iii) adheres to the reduction and refinement principles of laboratory animal use.

Published
2018
Full Text
View/download PDF

16. The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box

Author

te Brake, Lindsey H.M., de Knegt, Gerjo J., de Steenwinkel, Jurriaan E., van Dam, Teunis J.P., Burger, David M., Russel, Frans G.M., van Crevel, Reinout, Koenderink, Jan B., Aarnoutse, Rob E., te Brake, Lindsey H.M., de Knegt, Gerjo J., de Steenwinkel, Jurriaan E., van Dam, Teunis J.P., Burger, David M., Russel, Frans G.M., van Crevel, Reinout, Koenderink, Jan B., and Aarnoutse, Rob E.

Published
2018

21. Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosis

Author

de Steenwinkel, Jurriaan E. M., primary, ten Kate, Marian T., additional, de Knegt, Gerjo J., additional, Verbrugh, Henri A., additional, Aarnoutse, Rob E., additional, Boeree, Martin J., additional, den Bakker, Michael A., additional, van Soolingen, Dick, additional, and Bakker-Woudenberg, Irma A. J. M., additional

Published
2012
Full Text
View/download PDF

23. Distinctive Cytokines as Biomarkers Predicting Fatal Outcome of Severe Staphylococcus aureus Bacteremia in Mice.

Author

van den Berg, Sanne, Laman, Jon D., Boon, Louis, ten Kate, Marian T., de Knegt, Gerjo J., Verdijk, Rob M., Verbrugh, Henri A., Nouwen, Jan L., and Bakker-Woudenberg, Irma A. J. M.

Subjects
STAPHYLOCOCCUS aureus infections, CYTOKINES, BIOMARKERS, HEALTH outcome assessment, STAPHYLOCOCCUS aureus, BACTEREMIA, LABORATORY mice, ANTIBIOTICS, DECISION making in clinical medicine, THERAPEUTICS
Abstract

Invasive Staphylococcus aureus infections are frequently associated with bacteraemia. To support clinical decisions on antibiotic therapy, there is an urgent need for reliable markers as predictors of infection outcome. In the present study in mice, bacteraemia was established by intravenous inoculation of a clinical S. aureus isolate at the LD50 inoculum. As potential biomarkers for fatal outcome, blood culture (qualitative and quantitative), serum levels of C-reactive protein (CRP), as well as 31 selected cytokines and chemokines were assessed during the first three days of infection. A positive S. aureus blood culture, the quantitative blood culture, CRP levels, and levels of eight cytokines were indicative for the presence of S. aureus bacteraemia. However, only tumor necrosis factor (TNF) α, interleukin (IL) 1α, and keratinocyte chemoattractant (KC; a functional homologue of human IL-8) were each significantly elevated in eventually non-surviving infected mice versus eventually surviving infected mice. In severe S. aureus bacteraemia in mice, TNF-α, IL-1α, and KC are biomarkers predicting fatal outcome of infection. KC was a biomarker elevated irrespective the progression of infection, which is very interesting regarding clinical application in view of the heterogeneity of patients experiencing bacteraemia in this respect. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results